Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA:688796)
China flag China · Delayed Price · Currency is CNY
70.96
-1.87 (-2.57%)
At close: Feb 6, 2026

Biocytogen Pharmaceuticals (Beijing) Company Description

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.

It operates through five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody development, and Innovative drugs development.

The Gene-editing services segment provides the customized gene editing services based on animals as well as cells to meet the needs of basic science research and drug development of the customers; Pre-clinical pharmacology and efficacy evaluation segment provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; Animal models selling segment breeds and sells the animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; Antibody development segment utilises the Group’s own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and Innovative drugs development segment engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics.

The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial.

The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
CountryChina
Founded2008
IndustryBiological Products, Except Diagnostic Substances
Employees1,306
CEOYuelei Shen

Contact Details

Address:
12 Baoshen South Street
Beijing
China
Phone86 10 5696 7680
Websitebiocytogen.com

Stock Details

Ticker Symbol688796
ExchangeShanghai Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyCNY
SIC Code2836

Key Executives

NamePosition
Yuelei ShenChief Executive Officer
Bin LiuChief Financial Officer